

### AMENDMENTS TO THE SPECIFICATION

Please replace the section entitled "DRAWINGS" beginning with paragraph [0044] on page 11 and ending with paragraph [0060] on page 13 with the following section:

#### DRAWINGS

[0044] ~~Figure 1 shows~~Figures 1A-1C show the target cell populations following injection into mice vaccinated with the indicated *Listeria* strains or vehicle control. Reduced levels of antigen-specific target cells relative to non-specific target cells ~~indicates~~indicate *in vivo* cytotoxicity of T cells in response to the vaccination. Figure 1A shows *in vivo* cytotoxicity in mice vaccinated IV or IM with the  $\Delta actA$  mutant or the  $\Delta actA\Delta inlB$  double mutant. Figure 1B shows *in vivo* cytotoxicity in mice vaccinated IV with the  $\Delta actA$  mutant or the  $\Delta actA\Delta inlB$  double mutant. Figure 1C shows *in vivo* cytotoxicity in mice vaccinated IV with the  $\Delta actA\Delta inlB$  double mutant.

[0045] ~~Figure 2 shows~~Figures 2A-2C show the lungs of mice with established CT26 lung tumors given a therapeutic vaccination with mutant *Listeria* strains or a control (Figure 2A). Lung metastases are visible as spots on the lung. The survival of mice from two additional studies is plotted in Figures 2B-C.

[0046] ~~Figure 3 shows~~Figures 3A-3F show the results of IFN- $\gamma$  and TNF- $\alpha$  Intracellular Cytokine Staining (ICS) assays for splenic CD8<sup>+</sup> T cells from mice vaccinated with mutant *Listeria*, stimulated with SL8 OVA<sub>257-264</sub> peptide (Figures 3A-B), LLO<sub>190</sub> peptide (Figures 3C-D), or the LLO<sub>296</sub> peptide (Figures 3E-F). ("PCT" indicates data for the S-59/UVA inactivated cells.)

[0047] Figure 4 shows the results of IFN- $\gamma$  ICS assays for spleen cells from mice vaccinated (intravenously) with mutant *Listeria*, stimulated with SL8 OVA<sub>257-264</sub> peptide, live or S-59/UVA inactivated EL-4 cells, or live or S-59/UVA inactivated OVA-expressing EG7 cells.

[0048] Figure 5 shows the results of IFN- $\gamma$  ICS assays for spleen cells from mice vaccinated (intravenously) with varying doses of mutant *Listeria*, stimulated with SL8 OVA<sub>257-264</sub> peptide.

[0049] Figure 6 shows the results of IFN- $\gamma$  ICS assays for spleen cells from mice vaccinated via different routes with mutant *Listeria*, stimulated with SL8 OVA<sub>257-264</sub> peptide.

[0050] ~~Figure~~Figures 7A and 7B show the accelerated clearance of *Listeria monocytogenes*  $\Delta actA\Delta inlB$  strain *in vivo*. Bacteria levels in the liver over time are shown in the figure.

[0051] ~~Figure-Figures~~ 8A and 8B show the accelerated clearance of *Listeria monocytogenes*  $\Delta actA \Delta inlB$  strain *in vivo*. A time course of bacteria levels in the spleen is shown in the figure.

[0052] Figure 9 shows that the *Listeria monocytogenes*  $\Delta inlB$  strain and the *Listeria monocytogenes*  $\Delta actA \Delta inlB$  strain are attenuated for entry into non-phagocytic cells, but not phagocytic cells *in vitro*.

[0053] Figure 10 shows that high titer anti-*Listeria* serum inhibits uptake by non-phagocytic cells, but not by phagocytic cells.

[0054] Figure 11A shows the attenuation of DP-L4029 ( $\Delta actA$ ) *Listeria* strain containing OVA antigen as a function of psoralen S-59 concentration along with the measurement of OVA antigen presentation to a dendritic cell line. The bacterial log titer and % of antigen presentation relative to untreated (linear scale, 1 *Listeria* per DC 2.4 cell) are plotted vs. nM S-59 (dosed with 0.5 J/cm<sup>2</sup> UVA, washed *Listeria* once, dosed again with 5.5 J/cm<sup>2</sup> UVA).

[0055] Figure 11B shows the attenuation of DP-L4029  $\Delta uvrAB$  *Listeria* strain containing OVA antigen as a function of psoralen S-59 concentration along with the measurement of OVA antigen presentation to a dendritic cell line. The bacterial log titer and % of antigen presentation relative to untreated (linear scale, 1 *Listeria* per DC 2.4 cell) are plotted vs. nM S-59 (dosed with 0.5 J/cm<sup>2</sup> UVA, washed *Listeria* once, dosed again with 5.5 J/cm<sup>2</sup> UVA).

[0056] Figure 11C shows the attenuation of DP-L4029 ( $\Delta actA$ ) *Listeria* strain containing OVA antigen as a function of psoralen S-59 concentration along with the measurement of OVA antigen presentation to a dendritic cell line.

[0057] Figure 11D shows the attenuation of DP-L4029  $\Delta uvrAB$  ( $\Delta actA \Delta uvrAB$ ) *Listeria* strain containing OVA antigen as a function of psoralen S-59 concentration along with the measurement of OVA antigen presentation to a dendritic cell line.

[0058] Figure 12A shows the induction of OVA specific T cell response in the presence of anti-*Listeria* immunity.

[0059] Figure 12B shows that effective anti-tumor immune response is stimulated in the presence of *Listeria*-specific immunity.

[0060] Figure 12C shows that transfer of *Listeria* immune serum does not prevent priming of OVA-specific CD8<sup>+</sup> cells.